Skip to search formSkip to main contentSkip to account menu

BeneFIX

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
ObjectivesTo develop a recombinant human factor IX (rFIX) formulation equivalent to commercially available products in terms of… 
2017
2017
Dear Sir, Factor VIII and IX products with enhanced half-life are being introduced into routine clinical practice1. Not… 
2016
2016
a linear response in clotting efficacy up to 150 IU/kg, where they appear to saturate an extravascular compartment, because there… 
Highly Cited
2014
Highly Cited
2014
Due to variability in the one-stage clotting assay, the performance of new factor IX (FIX) products should be assessed in this… 
2013
2013
Head‐on comparative studies of factor IX (FIX) concentrates performed under standardized conditions are rarely conducted… 
2011
2011
Abstract 2266 Recombinant Factor IX Fc fusion (rFIXFc) was designed to be a long-lasting version of recombinant FIX that has the… 
Highly Cited
2007
Highly Cited
2007
Summary.   BeneFix®, the only recombinant factor IX (FIX), has been reformulated. The reformulation involves a change in diluent… 
2001
2001
The safety and efficacy of adjusted continuous infusion (CI) of recombinant factor IX (FIX; BeneFix®) was assessed in vitro and… 
1999
1999
The effects of a recombinant factor IX product (BeneFix), and of five plasma‐derived factor IX products, AlphaNine, Immunine…